House Republicans on Thursday rejected a Trump administration-backed drug pricing amendment for a health care spending bill, according to The Hill.
In a bid to boost pricing transparency, the amendment would have required drugmakers disclose drug prices in direct-to-consumer TV ads.
Senators on both sides of the aisle cleared the bill in August.
A sponsor of the bill, Sen. Dick Durbin, a Democrat, suggested pharmaceutical companies played a role in the bill’s failure.
“When are we going to stand up to Big Pharma?” he asked.